信铭生命科技中期报告 2025

(Stock Code 股份代號 : 00474)(Incorporated in the Cayman Islands with limited liability)（於開曼群島註冊成立的有限公司） 2025INTERIM REPORT中期報告 Contents 2Corporate Information4Management Discussion and Analysis13Disclosure of Interests16Corporate Governance19Condensed Consolidated Statement of Profit or Loss andOther Comprehensive Income22242527 Condensed Consolidated Statement of Financial PositionCondensed Consolidated Statement of Changes in EquityCondensed Consolidated Statement of Cash FlowsNotes to the Condensed Consolidated Financial Statements CORPORATE INFORMATION EXECUTIVE DIRECTORS Dr. Zhiliang Ou,J.P. (Australia)Mr. Fok Chi Tak NON-EXECUTIVE DIRECTOR Ms. Jiang Yang INDEPENDENT NON-EXECUTIVE DIRECTORS Mr. Chan Ming Sun JonathanMr. Lam Kwan SingMr. Mak Yiu Tong AUDIT COMMITTEE Mr. Chan Ming Sun Jonathan(Chairman of Committee)Mr. Lam Kwan SingMr. Mak Yiu Tong EXECUTIVE COMMITTEE Dr. Zhiliang Ou,J.P. (Australia)Mr. Fok Chi Tak REMUNERATION COMMITTEE Mr. Chan Ming Sun Jonathan(Chairman of Committee)Dr. Zhiliang Ou,J.P. (Australia)Mr. Lam Kwan Sing NOMINATION COMMITTEE Mr. Mak Yiu Tong(Chairman of Committee)Dr. Zhiliang Ou,J.P. (Australia)Mr. Chan Ming Sun JonathanMr. Lam Kwan SingMs. Jiang Yang AUTHORISED REPRESENTATIVES Mr. Fok Chi TakDr. Zhiliang Ou,J.P. (Australia) COMPANY SECRETARY Mr. Siu Chun Pong Raymond LEGAL ADVISER Raymond Siu & Lawyers 2Aceso Life Science Group LimitedInterim Report 2025 CORPORATE INFORMATION AUDITOR Moore CPA Limited PRINCIPAL BANKERS Shanghai Commercial Bank LimitedThe Hongkong and Shanghai Banking Corporation LimitedNanyang Commercial Bank, Ltd.Bank of China (Hong Kong) LimitedThe Bank of East Asia Limited PRINCIPAL SHARE REGISTRAR AND TRANSFEROFFICE IN CAYMAN ISLANDS Suntera (Cayman) LimitedSuite 3204, Unit 2A, Block 3, Building DP.O. Box 1586, Gardenia CourtCamana BayGrand Cayman, KY1–1100Cayman Islands Suntera (Cayman) LimitedSuite 3204, Unit 2A, Block 3, Building DP.O. Box 1586, Gardenia CourtCamana BayGrand Cayman, KY1-1100Cayman Islands HONG KONG BRANCH SHARE REGISTRAR ANDTRANSFER OFFICE 183171712-1716 Computershare Hong Kong Investor Services LimitedShops 1712–171617th Floor, Hopewell Centre183 Queen’s Road East,Wan Chai Hong Kong REGISTERED OFFICE Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1–1111Cayman Islands Cricket SquareHutchins DriveP.O. Box 2681Grand Cayman KY1-1111Cayman Islands PRINCIPAL PLACE OF BUSINESS IN HONG KONG 6-8252501-2509 Rooms 2501–2509,25/F Shui On Centre6–8 Harbour Road, WanchaiHong Kong STOCK CODE 474 474 WEBSITE www.acesogrouphk.com www.acesogrouphk.com The above information is updated to the date of this interim report. MANAGEMENT DISCUSSION AND ANALYSIS BUSINESS REVIEW Strategic Transformation and Business Realignment The current period of six months ended 30 September 2025 (the “Period’)marked a significant turning point in Aceso Life Science Group Limited’s (the“Company”) strategic direction and operational focus. In the past, the Companyoperated as a diversified portfolio investment holding entity through its majorsubsidiary, Hao Tian International Construction Investment Group Limited(“HTICI”), which engaged in a broad spectrum of business activities. Theseincluded asset management, securities investment, securities brokerage andother financial services, rental and sales of construction machinery and spareparts, repair and maintenance and transportation services and money lendingservices. This multi-pronged approach allowed the Company to explore variousgrowth avenues and maintain a diversified revenue base. However, in May 2025, the Company completed the deemed disposal of itsshares in HTICI, resulting in a fundamental shift in its business model andstrategy. With HTICI ceasing to be a subsidiary of the Company, the Companyhas streamlined its operations and repositioned itself as an enterprise focusingon the property leasing business. This strategic realignment was driven by adesire to concentrate on the Company’s core competencies, enhance operationalefficiency and deliver stable and long-term value to the shareholders. The transition from a diversified portfolio investment holding company toa focused business specializing in the property leasing business, reflects adeliberate and forward-looking strategy of the Company. It enables the Companyto capitalize and focus on the strength of its prime commercial property asset inCentral London, United Kingdom (the “UK Property”), while reducing exposureto the volatility of the capital-intensive sectors and the related uncertainties. Core Business: Property Leasing in London Following the deemed disposal of its shareholding in HTICI in May 2025, theCompany’s current major operating asset is a high-quality commercial propertylocated within a traditional business district in Central London. The UK Propertyserves as the cornerstone of the Company’s revenue generation and long-term growth strategy. The building is tenanted by a portfolio of r